Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories about which company holds the upper hand heading into a pivotal summer of reports and pricing resets.
(Bloomberg) -- Apnimed Inc., a late-stage drug developer focused on sleep apnea rose 6.3% on Friday after raising $192 million in an upsized US initial public offering.Most Read from BloombergSingapore's Gated Island for the Rich Is Marred by Decayed HomesAnthropic AI Models Hacked Three Organizations During TestsMicrosoft’s $450 Billion Jump Is Biggest in Stock Market HistoryChip Stocks Post Biggest Advance Since April 2025: Markets WrapUS Strikes Iran Again as Conflict Spreads Across Middle Ea
Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's Novo Nordisk announced overnight that its experimental cardiovascular drug, ziltivekimab — to treat heart disease, kidney disease and inflammation — failed in the late-stage trial.
AMD stock keeps its latest pullback contained compared with many other chip stocks as its second-quarter earnings report looms large.
The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.
Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The investment will support Resilience’s advanced manufacturing operations in Cincinnati.
This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the S
MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?
Expansion adds at least 400 jobs, taking Resilience's Ohio headcount above 1,400
Eli Lilly (NYSE:LLY) has joined Illumina's Billion Cell Atlas alliance as a foundational participant. The alliance is building what is described as the world's largest genome-wide genetic perturbation dataset. The Billion Cell Atlas is sequencing hundreds of millions of cells to map disease mechanisms and find new drug targets. Eli Lilly enters this genomic data effort with a stock that has seen very strong multi year appreciation. NYSE:LLY is trading at $1,210.02, with the share price up...
Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]
Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.
But is that performance sustainable?
Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lilly's pipeline is on track to pick up a handful of interesting new programs.
Will this pharma company become a new leader in the weight loss market?
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.
Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
